Contents
Special Issue Topic

Posttranslational Modifications in Health and Disease

Submission Deadline: December 31, 2024

Guest Editor

Prof. Oliver Krämer E-Mail

Institute of Toxicology, Johannes-Gutenberg University of Mainz, Mainz, Germany

About the Special lssue

Posttranslational modifications increase the functions of proteins and thereby regulate key biological functions. Examples of posttranslational modifications are acetylation, ubiquitinylation, and sumoylation of lysine residues and phosphorylation of serine, threonine, and tyrosine residues. The balance between the attachment and removal of posttranslational modifications is dysregulated in severe diseases including cancers, neurodegeneration, and immune failure. Therefore, enzymes modulating posttranslational modifications are in the focus of current research and drug development. Increasing evidence indicates that inhibitors of dysregulated posttranslational modification patterns are useful to treat humans.
In this Special Issue, short and long original research articles, reviews, and case reports are welcome. Submitted articles should be pertinent to the analysis of posttranslational modifications that are dysregulated in tumor cells. This also applies to drugs that correct aberrant modifications to combat cancer. Basic research articles as well as reports with a strong clinical focus are welcome.

Keywords: acetylation; cancer; posttranslational modification acetylation; health and disease; inhibitor(s); methylation; SUMO; tumorigenesis; phosphorylation; posttranslational modification(s); ubiquitin

Published Articles

Open Access Review
Post-translational modulation of cell signalling through protein succinylation
Katharina F. Kubatzky ... Dayoung Yu
Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1260–1285
5032 60 6
Open Access Review
Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy
Mansi Joshi ... Abhijit De
Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1227–1248
3147 68 3
Open Access Review
Medicinal chemistry advances in targeting class I histone deacetylases
Diaaeldin I. Abdallah ... Patrick T. Gunning
Published: August 31, 2023 Explor Target Antitumor Ther. 2023;4:757–779
4045 94 8
Open Access Review
Protein ISGylation: a posttranslational modification with implications for malignant neoplasms
Angeles C. Tecalco-Cruz, Jesús Zepeda-Cervantes
Published: August 31, 2023 Explor Target Antitumor Ther. 2023;4:699–715
2583 38 4